Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review
Authors:
- Simon R. KnightSKSimon R. Knight
- Neil K. RussellNRNeil K. Russell
- Leticia BarcenaLBLeticia Barcena
- Peter J. MorrisPMPeter J. Morris
- 27 March 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (6) , 785-794
Abstract
Mycophenolate mofetil (MMF) has increasingly replaced azathioprine (AZA) as the antimetabolite of choice in immunosuppressive protocols. Initial trials comparing MMF with AZA in patients receiving cyclosporine A sandimmune showed a clinical benefit in reducing the incidence of acute rejections. It has been questioned whether this benefit remains significant when using newer formulations of cyclosporine A (neoral) and tacrolimus. Literature searches were performed using the Transplant Library, Cochrane library, Medline, and Embase for all randomized controlled trials directly comparing MMF with AZA in renal transplant recipients. Trials were assessed for quality using the Jadad scoring system. Trials were pooled using meta-analysis software. Confidence intervals were set at 95%. Nineteen relevant studies were identified, including a total of 3143 patients. MMF significantly reduces the risk of acute rejection when used in combination with any calcineurin inhibitor (relative risk 0.62, 0.55–0.87, P<0.00001). The hazard for graft loss, including death with a functioning graft, is also significantly reduced in patients treated with MMF (hazard ratio 0.76, 0.59–0.98, P=0.037). There is no significant difference in patient survival or renal transplant function between groups. Risk of adverse events, including cytomegalovirus infection, anemia, leukopenia or rates of malignancy, does not differ significantly. A greater risk of diarrhea is seen in MMF-treated patients. We have shown that MMF used with a calcineurin inhibitor does indeed confer a clinical benefit over AZA by reducing the risk of acute rejection and also possibly reducing graft loss. This effect is independent of whether MMF is used in combination with sandimmune, neoral or tacrolimus.Keywords
This publication has 43 references indexed in Scilit:
- Long-Term Graft Outcome with Mycophenolate Mofetil and Azathioprine: A Paired Kidney AnalysisTransplantation, 2006
- Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trialThe Lancet, 2004
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995
- Prolonged Survival of Human-Kidney Homografts by Immunosuppressive Drug TherapyNew England Journal of Medicine, 1963
- Kidney Transplantation in Modified RecipientsAnnals of Surgery, 1962